Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease

Journal of Neuroimmunology

Volumn 79, Issue 1, 1997, Pages 54-61

  Sommer, N ^a,b   Martin, R ^a,b   McFarland, H F ^a   Quigley, L ^a   Cannella, B ^c   Raine, C S ^c   Scott, D E ^d   Loschmann P A ^b   Racke, M K ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Hoppe Seyler Str 3 ^*  (Germany)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cytokine; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Phosphodiesterase type 4; Rolipram; Tumor necrosis factor

Indexed keywords

CYTOKINE; MYELIN BASIC PROTEIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DEMYELINATING DISEASE; DEMYELINATION; DRUG THERAPY; FEMALE; GENE EXPRESSION; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AUTOIMMUNE DISEASES; CELL COUNT; CELLS, CULTURED; DEMYELINATING DISEASES; FEMALE; LYMPH NODES; MICE; MICE, INBRED STRAINS; MYELIN BASIC PROTEINS; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; ROLIPRAM; T-LYMPHOCYTES;

EID: 0030660328     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00111-2     Document Type: Article

References (33)

1. Acha-Orbea H., Steinman L., McDevitt H. T cell receptors in murine autoimmune diseases. Annu. Rev. Immunol. 7:1989;371-406.
2. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
3. Bottomly, K., Davis, L.S., Lipsky, P.E. (1991), Measurement of human and murine interleukin 2 and interleukin 4. In: Coligan, J.E., Kruisbeck, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.) Current Protocols in Immunology. John Wiley & Sons, New York, p. 6.3.1.
4. Danielpour D., Dart L.L., Flanders K.C., Roberts A.B., Sporn M.B. Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-β1 and TGF-β2) secreted by cells in culture. J. Cell. Physiol. 138:1989;79-86.
5. Deibler G.E., Martenson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous system tissue of several mammal species. Prep. Biochem. 2:1972;139-165.
6. Genain C.P., Roberts T., Davis R.L., Nguyen M.-H., Ucchelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA. 92:1995;3601-3605.
7. Giegerich G., Pette M., Meinl E., Epplen J.T., Wekerle H., Hinkkanen A. Diversity of T cell receptor alpha and beta chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes. Eur. J. Immunol. 22:1992;753-758.
8. Maini R.N., Elliott M.J., Brennan F.M., Williams R.O., Chu C.Q., Paleolog E., Charles P.J., Taylor P.C., Feldman M. Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144:1995;195-223.
9. Marcoz P., Prigent A.F., Lagarde M., Némoz G. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phsophodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44:1993;1027-1035.
10. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
11. Martin R., Utz U., Coligan J.E., Richert J.R., Flerlage M., Robinson E., Stone R., Biddison W.E., McFarlin D.E., McFarland H.F. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J. Immunol. 148:1992;1359-1366.
12. Monastra G., Cross A.H., Bruni A., Raine C.S. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination. Neurology. 43:1993;153-163.
13. Prabhakar U., Lipshutz D., Bartus J.O., Slivjak J., Smith E.F., Lee J.C., Esser K.M. Characterization of cAMP-dependent inhibition of LPS-induced TMFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16:1994;805-816.
14. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146:1991;3012-3017.
15. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Röcken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
16. Renno T., Krakowski M., Piccirillo C., Lin J., Owens T. TNF-α expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental encephalomyelitis. J. Immunol. 154:1995;944-953.
17. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1993;1745-1751.
18. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
19. Seder R.A., Paul W.A., Davis M.M., Fazekas de St. Groth B. The presence of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J. Exp. Med. 176:1992;1091-1098.
20. Selmaj K., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
21. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:1995;135-141.
22. Semmler J., Wachtel H., Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int. J. Immunopharmacol. 15:1993;409-413.
23. Sinha B., Semmler J., Eisenhut T., Eigler A., Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25:1995;147-153.
24. Sommer N., Löschmann P.-A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmüller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses, cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:1995;244-248.
25. Svetic A.F., Finkelman F.D., Jian Y.C., Dieffenbach C.W., Scott D.E., McCarthy K.F., Steinberg A.D., Gause W.C. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 147:1991;2391-2397.
26. Torphy T.J., Zhou H.L., Cieslinski L.B. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263:1992;1195-1205.
27. Torphy T.J., Zhou H.L., Foley J.J., Sarau H.M., Manning C.D., Barnette M.S. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J. Biol. Chem. 270:1995;23598-23604.
28. Utz U., Brooks J.A., McFarland H.F., Martin R., Biddison W.E. Heterogeneity of T-cell receptor α-chain complementarity-determining region 3 in myelin basic protein-specific T cells increases with severity of multiple sclerosis. Proc. Natl. Acad. Sci. USA. 91:1994;5567-5571.
29. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:1992;411-452.
30. Wachtel H., Schneider H.H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoanime-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology. 25:1986;1119-1126.
31. Wang T., Sheppard J.R., Foker J.E. Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis. Science. 201:1978;155-157.
32. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., Linington C. Animal models,. Ann Neurol. 36(6(suppl.)):1994;S47-S53.
33. Zeller E., Stief H.J., Pflug B., Sastre-y-Hermandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 17:1984;188-190.